Aadi Bioscience Q1 FYARRO sales $5.4M; PRECISION1 fully enrolled; net loss $18.3M

Whitehawk Therapeutics, Inc.

2024-Q1 EPS reported -$0.68 revenue$5,353,000

FYARRO net sales $5.4M, down 8.8% YoY due to distributor ordering and fewer patient initiations.
Net loss $18.3M vs $15.2M in Q1 2023; cash $88.3M expected to fund operations into Q4 2025.
PRECISION1 trial fully enrolled; two-thirds interim analysis expected Q3 2024, full data early 2025.
Terminated Mirati/BMS collaboration for adagrasib combo; prioritizing Phase 2 trials in EEC and NETs.
Management expects return to sales growth in Q2 2024.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 1.0

Whitehawk Therapeutics, Inc. reported first quarter ended March 31, 2024 results: revenue $5.4 million, net income $18.3 million.

Period: first quarter ended March 31, 2024
Revenue: $5.4 million
Net income: $18.3 million
Result: reported results

Exact text from the filing

for the First Quarter 2024 and Provides Corporate Update Fully enrolled registration-intended PRECISION1 trial; two-thirds interim analysis planned for Q3 2024 FYARRO® sales of $5.4 million for Q1 2024, reflects distributor ordering patterns and fewer commercial patient initiations at the start of the year Conference call to be held today at 8:30 am EDT LOS ANGELES,

View on SEC.gov

1053 earnings releases filed in the last 30 days. Browse all earnings releases →

Whitehawk Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001628280-24-021381

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.